Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Datascope brings Anestar production to US:

This article was originally published in Clinica

Executive Summary

Datascope is shifting production of its Anestar and Anestar S anaesthesia delivery systems from Germany to its facility in New Jersey, having bought the manufacturing rights to the devices from its OEM partner. The move will enable the company to enhance its line of anaesthesia systems without the restrictions of an OEM agreement as well as giving it a competitive boost in the anaesthesia delivery and OR (operating room) patient monitor markets. Datascope, of Montvale, New Jersey, estimates that these two markets together generate $700m in annual worldwide sales.

You may also be interested in...



EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.

Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements

Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel